Ginkgo Bioworks Holdings Inc - Class A risk profile
59 Elevated one input has moved against it
Measured 21 October 2026 from DNA's filed statements. Recomputed nightly.
59 (Elevated), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 66 | Stretched | Volatile | One-year price volatility — 99.1% |
| Operating pressure | 7 | Contained | Worsening | Costs outgrowing revenue — -8.6 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.04x |
| Leverage and coverage | 45 | Elevated | Worsening | Net debt to EBITDA |
| Competitive position | 80 | Acute | Stable | Operating-margin gap against peers — -185.9 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Ginkgo Bioworks Holdings Inc - Class A